The comorbid patients with arterial hypertension, chronic heart failure and chronic kidney disease: the role of fosinoprile

This article discusses clinicopharmacological niches of fosinopril, one of the most popular ACE inhibitors in daily outpatient practice. The authors cover aspects, where fosinopril has advantages over other ACE inhibitors and angiotensin II receptor blockers (sartans) from the point of view of therapy, cardiology and clinical pharmacology. The theses taken as a basis of the article are confirmed by the authors, who named and reviewed the leading clinical trials of fosinopril and its potentially possible combinations with diuretics and calcium channel blockers. The article also covers issues and satellite phenomena of “vascular” comorbidity in patients with arterial hypertension, chronic heart failure and chronic kidney disease; describes the mechanisms of their development and mutual aggravation; examines the points of administration and the evidence for the efficacy and safety of fosinopril in this cohort of patients. One of the main theses of this article is the importance of organ-protection (-cardio, -nefro, -angio). The main directions and postulates of its implementation are provided using the example of ACE inhibitors.

1. Feinstein AR. Pre-therapeutic classification of co-morbidity in chronic disease. Journal Chronic Disease, 1970, 23(7): 455-468.

2. Charlson ME, Sax FL. The therapeutic efficacy of critical care units from two perspectives: a traditional cohort approach vs a new case-control methodology. J Chronic Dis, 1987, 40(1): 31-9.

3. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hos-pitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol, 2007, 50(8): 768-777.

4. Bakris GL, Weir MR. ACE inhibitor-assocoated elevations in serum creatinine: Is this a cause for concern? Arch. Intern. Med., 2000, 160: 685-693.

5. Maschio D, Alberti D, Janin G. The Angiotensin-converting-enzyme Inhibition in Progressive Renal Insufficiency Study. N Engl J Med, 1996, 334(15): 939-45.

6. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non– diabetic proteinuric chronic nephropathies. Kidney Int, 1998, 53: 1209–1216.

7. ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34: 2159-2219. doi: 10.1093/eurheartj/eht151.

8. Wald DS, Law M, Morris JK et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta–analysis on 11000 Participants from 42 Trials. The American Journal of Medicine, 2009, 122: 290-300.

9. Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med, 2003, 348: 583-92.

10. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabet Care, 1998, 21: 597-603.

11. Veller W. Treatment of Senile hypertension. The fosinopril in old patients study. AJH, 1997, 10: 255-261.

12. Olivier PB, Germain ML, Carette BD et al. Elevation of serum creatinine following fosinopril therapy. Ann. Pharmacother, 1999, 33: 382-383.

13. Berdah J, Guest M, Salvador M. Study of the efficacy and safety of fosinopril in general practice in 19,435 hypertensive patients (FLIGHT Study). Ann Cardiol Angeiol, 1998, 47(3): 169-175.

14. Borghi C et al. Post acute myocardial infarction. The fosinopril in acute myocardial infarction study (FAMIS). Am J Hypertens, 1997, 10: 247–54.

15. Asselbergs FW, Diercks GF, Hillege HL et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation, 2004, 110(18): 2809–16.

16. Zanchetti A, Crepaldi G, Bond MG et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized doubleblind trial. Stroke, 2004, 35(12): 2807-2812.

17. Chazova IE. The first results of the PHAGOT study (Pharmaco-economic assessment of the ACE inhibitors use in the outpatient treatment of patients with complicated course of arterial hypertension). Consillium Medicum, 2002, 11: 596-598.

18. Mareev VYu. Pharmacoeconomic assessment of the ACE inhibitor use in the outpatient treatment of patients with heart failure (FASON). Serdechnaya nedostatochnost, 2002, 3 (1): 38-39.